Welcome to the 2022 ASTRO Annual Meeting! Whether you’re attending in person or virtually, I’m sure you will find this an exciting and thought-provoking meeting. In addition to great educational and scientific presentations, we’ll explore a wide-ranging array of topics relevant to our specialty.

The theme of this year’s meeting is Artificial Intelligence (AI) and Emotional Intelligence (EI): Caring for the Patient in a Wireless World. Technological innovation has transformed radiation oncology and will continue to incorporate AI applications throughout our practice. We need to be thoughtful about how we use this technology and mindful that the heart of our specialty is patient care, an empathetic human interaction. The meeting theme provides a platform for an eclectic meeting, combining tradition and innovation.

For the early birds among us, check out the 8:00 a.m. Sunday morning sessions. I’m looking forward to “Exploring Ethical Challenges in Artificial Intelligence.” Don’t miss our Clinical Trials Session today from 9:30 a.m. to 11:00 a.m. We’ll be featuring the results of six exciting studies covering different areas of practice, including the first-in-human study of proton FLASH radiotherapy and the impact of direct patient care for medical physicists.

Our Presidential Symposium will be held this afternoon from 12:00 p.m. to 4:00 p.m. The four sessions will explore the meeting theme. The first session, moderated by Sanjay Aneja, MD, Catherine Park, MD, FASTRO, and Todd Pawlicki, PhD, FASTRO, will discuss “AI Opportunities in Today’s Patient Journey – Cutting-Edge AI in Radiation Oncology.” The second session “Prevention and Mitigation of Radiation Toxicity,” will be moderated by Brian Marples, PhD. The session will explore the biology and prevention of normal tissue injury and patient-centered clinical trials on radiation toxicity. The third session will revisit AI in a broader context. This session “The ‘Meta’ Vision—How Can AI Help Solve Issues of Equity/Access/Value in Radiation Oncology,” will be moderated by Julian C. Hong, MD, MS. The final session of the symposium “Human Doctors, Human Patients” will focus on aspects of practice related to emotional intelligence: communication, empathy, quality of life and the pivotal role of hope in patient care.

This year we have two amazing keynote speakers who exemplify the dual nature of our meeting theme. Monday morning our first keynote speaker will be...
MRIdian Stereotactic MRI-Guided Adaptive Radiotherapy (SMART) is the only treatment that integrates diagnostic-quality MR imaging, streamlined on-table adaptive replanning, and continuous, real-time, soft tissue tracking and automated beam gating. MRIdian SMART allows clinical teams to define tighter treatment margins, deliver ablative doses in five or fewer fractions, while avoiding unwanted dose to OARs, and minimizing toxicities without relying on implanted markers.*

Join the community conducting breakthrough research while delivering unmatched clinical results today. Discover how MRIdian SMART enables teams to treat and prove what others can’t.

Visit ASTRO booth #3770 to demo new innovations.

Sunday, October 23, 2022

9:15 a.m. - 9:30 a.m.
Welcome 01 - Welcome to ASTRO’s Annual Meeting
Room at Night Ballroom

9:30 a.m. - 11:00 a.m.
CT 01 - Clinical Trials Session
Stars at Night Ballroom

9:30 a.m. - 10:45 a.m.
PRO 09 - PRO: Personalized Treatment for Non-Melanoma Skin Cancer
Hemisfair Ballroom C2/C3

10:00 a.m. - 5:00 p.m.
Exhibit Hall Opens
Exhibit Halls 2-4

11:00 a.m. - 2:30 p.m.
ASPP 01 - Aspiring Scientists and Physicians Program
Room 207

11:00 a.m. - 12:15 p.m.
PRO 10 - PRO: Considerations for Treatment of PSMA-Stage High-Risk Patients
Hemisfair Ballroom C2/C3

12:00 p.m. - 1:00 p.m.
PS 01 - Presidential Symposium: Session I – AI Opportunities in Today’s Patient’s Journey—Cutting-Edge AI in Radiation Oncology
Stars at Night Ballroom

1:00 p.m. - 2:00 p.m.
PS 02 - Presidential Symposium: Session II – Prevention and Mitigation of Radiation Toxicity
Stars at Night Ballroom

2:00 p.m. - 3:00 p.m.
ET 01 - Help Ukraine!
Industry Expert Theater 1

2:00 p.m. - 3:00 p.m.
PS 03 - Presidential Symposium: Session III – The “Meta”Vision—How Can AI Help Solve Issues of Equity/Access/Value in Radiation Oncology
Stars at Night Ballroom

3:00 p.m. - 6:00 p.m.
Master Class 03 - Goalsetting, Difficult Conversations and Leading “Up”
Room 302

3:00 p.m. - 4:00 p.m.
PS 04 - Presidential Symposium: Session IV – Human Doctors, Human Patients
Stars at Night Ballroom

4:00 p.m. - 5:00 p.m.
ASTRO 2022 Tweet Up
ASTRO sign near the ASTRO Resource Center

4:00 p.m. - 5:00 p.m.
Exhibit Hall Networking Break
Halls 2-4

4:45 p.m. - 6:00 p.m.
EDU 03 – When Should I Hold Radiation? – Delivery of Radiation with Novel Systemic Agents for Breast Cancer
Room 217

4:45 p.m. - 6:00 p.m.
EDU 04 - State of the ART: Clinical, Technical and Practical Considerations in Adaptive Radiation
Room 006

4:45 p.m. - 6:00 p.m.
International 03 - Peer Review for Global Interobserver Variations in Delineation and Plan Quality Assessment
Room 008

4:45 p.m. - 6:00 p.m.
Joint 01 - Live SA-CME - ASTRO/ASCO/SNO Joint Session - Brain Metastases: A Case-Based Interactive Overview of the 2022 ASTRO and ASCO/SNO/ASTRO Practice Guidelines
Hemisfair Ballroom C1

4:45 p.m. - 6:00 p.m.
Panel 03 - Successful Implementation of Global Oncology Research: Decolonization and Health Equity Centering as Strategies for Overcoming Historic Barriers and Obstacles
Room 007 C/D

4:45 p.m. - 6:00 p.m.
Panel 04 - Manipulating Metabolism to Enhance Radiation Therapy
Room 214

4:45 p.m. - 6:00 p.m.
Poster Q&A 01 - Lung Cancer and DEIH
Exhibit Hall 1

4:45 p.m. - 6:00 p.m.
QP 03 - Phys 1 - Imaging and Response Assessment
Room 303

4:45 p.m. - 6:00 p.m.
SS 04 - GI 1 - Esophageal Cancers: The Pros and Cons of Combined Modality Therapy
Room 301

4:45 p.m. - 6:00 p.m.
SS 05 - Palliative 1 - Novel Approaches to Palliative and Supportive Care: Improving Toxicity, Efficacy, and Equity
Room 007 A/B

5:00 p.m. - 6:00 p.m.
ARRO 02 - ARRO Mentoring and Networking Event
Room 004

7:00 p.m. - 8:00 p.m.
LGBTQIA+ Meet Up
Grand Hyatt, Bowie B
International Radiation Oncology Society Network (IRON): A unified voice in addressing global cancer challenges

BY MAY WAHAB, MD, PhD, FASTRO, AND EKATERINA HARSDFORD, INTERNATIONAL ATOMIC ENERGY AGENCY

CANCER IS A LEADING CAUSE OF MORTALITY WORLDWIDE, accounting for nearly 10 million deaths in 2020.1 More than 50% of cancer patients will require radiation therapy during their oncological journey. However, the availability of radiation therapy services and access to treatment are not equal globally, especially in low- and middle-income countries.2

The radiation oncology community has realized that better cooperation is needed in order to address the field’s many challenges, and that national and international stakeholders must prioritize cancer issues.3

In view of these growing challenges and opportunities, the International Atomic Energy Agency’s (IAEA) Human Health Division organized a Technical Meeting on Global Cancer Care in July 2020 “to promote global collaboration in radiation oncology, in efforts to improve access to and implementation of radiotherapy globally and ensure that radiation oncology is supported… through meaningful research and other collaborations.”4 Leaders in the field of radiation oncology, including ASTRO, editors of major journals and experts from leading institutions discussed the best ways to raise awareness of the importance of radiation oncology.4

Five recommendations were put forward, the fifth of which was the creation of a global radiotherapy society network — the International Radiation Oncology Society Network (IRON).4

The IAEA subsequently convened the leaders of regional societies to prepare the terms of reference and discuss IRON’s structure. The newly formed IRON will serve as a vehicle for sharing information, promoting communication among societies and coordinating worldwide responses to complex challenges, with the alternate aim of improving care for patients. The network will encourage regional radiation oncology leaders to meet three times a year at society meetings to discuss goals in education, training and research, as well as to coordinate activities and respond to challenges.

IRON will primarily be a discursive rather than an implementing body, with operationalization coordinated through existing mechanisms. As an international network, IRON will assume a greater role on the global stage by facilitating consultations among societies to address common issues and coordinate worldwide responses to complex challenges, with the alternate aim of improving care for patients. The network will encourage regional radiation oncology leaders to meet three times a year at society meetings to discuss goals in education, training and research, as well as to coordinate activities and respond to challenges.

IRON will cover the major regions of the world and will include:

- The African Organisation for Research and Training in Cancer (AORTIC)
- The American Society for Radiation Oncology (ASTRO)
- The Asociación Ibero-Latinoaericanca de Terapia Radiante Oncológica (ALATRO)
- The European Society for Therapeutic Radiology and Oncology (ESTRO)
- The Federation of Asian Organizations for Radiation Oncology (FARO)
- The Royal Australian and New Zealand College of Radiologist (RANZCR)

During the first year of its inception, the regional societies will convene at three society annual meetings per year, the first of which was held yesterday at ASTRO.

A stepwise expansion to include other interested societies will follow. The presidency of IRON will be for one year and then rotate among member societies. ESTRO will assume the inaugural leadership role, and Ben Slotman, MD, PhD, from ESTRO will fulfill the principal coordination and leader’s role in the upcoming year.

The formation of IRON will be acknowledged at the 2022 ASTRO Annual Meeting on Monday, October 24 at 1:00 p.m. in the address by ASTRO President Geraldine Jacobson, MD, MPH, MBA, FASTRO.

In addition, information about IRON will be presented by May Abdel-Wahab, MD, PhD, FASTRO, Director of IAEA’s Human Health Division, during the joint ASTRO-ESTRO session on Tuesday, October 25, 8:00 a.m., Room 206.

REFERENCES
**Best™ Cyclotron Systems**

**Best Model 200 Sub-Compact Self-Shielded Cyclotron**

**Best Model 70p Cyclotron for Radioisotopes Production and Research**

**Best Model B35ADP Alpha/Deuteron/Proton Cyclotron**

**Best Particle Therapy 400 MeV ion Rapid Cycling Medical Synchrotron (iRCMS)**

**NEW! Best Model 150p Cyclotron—Variable Energy Proton Beam for Radiation Therapy (Patent Pending)**

<table>
<thead>
<tr>
<th>Cyclotron Type</th>
<th>Energy Range</th>
<th>Applications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Best Model 200</td>
<td>1–9 MeV</td>
<td>Low energy, self-shielded compact system capable of producing: $^{18}$FDG, Na$^{18}$F, $^{11}$F-MISO, $^{18}$FLT, $^{18}$F-Choline, $^{18}$F-DOPA, $^{18}$F-PSMA, $^{11}$C, $^{13}$N, $^{68}$Ga and more!</td>
</tr>
<tr>
<td>Best Cyclotrons</td>
<td>1–3 MeV</td>
<td>Deuterons for materials analysis (Patent Pending)</td>
</tr>
<tr>
<td>Best Cyclotrons</td>
<td>70–150 MeV</td>
<td>For Proton Therapy (Patent Pending)</td>
</tr>
<tr>
<td>Best 15p Cyclotron</td>
<td>3–90 MeV</td>
<td>High current proton beams for neutron production and delivery (Patent Pending)</td>
</tr>
<tr>
<td>Best 15p Cyclotron</td>
<td>1–15 MeV</td>
<td>Proton only, capable of high current up to 1000 Micro Amps, for medical radioisotopes</td>
</tr>
<tr>
<td>Best 20u/25p Cyclotrons</td>
<td>20, 15–25 MeV</td>
<td>Proton only, capable of high current up to 1000 Micro Amps, for medical radioisotopes</td>
</tr>
<tr>
<td>Best 35p/35adp Cyclotrons</td>
<td>15–35 MeV</td>
<td>Proton or alpha/deuteron/proton, capable of high current up to 1000 Micro Amps, for medical radioisotopes</td>
</tr>
<tr>
<td>Best 70p Cyclotron</td>
<td>35–70 MeV</td>
<td>Proton only, capable of high current up to 1000 Micro Amps, for medical radioisotopes</td>
</tr>
<tr>
<td>Best 150p Cyclotron</td>
<td>From 70 MeV to 150 MeV</td>
<td>For all Medical Treatments including Benign and Malignant Tumors, Neurological, Eye, Head/Neck, Pediatric, Lung Cancers, Vascular/Cardiac/Stenosis/Ablation, etc. (Patent Pending)</td>
</tr>
</tbody>
</table>

**NEW**

Best Medical International, Inc. 7643 Fullerton Road, Springfield, VA 22153 USA

* Certain products shown are not available for sale currently.

Copyright © 2022 TeamBest Global Companies
2022 Graduating Resident Survey Results at the ARRO Annual Seminar

BY AMISHI BAJAJ, MD, CHAIR, ARRO EXECUTIVE COMMITTEE, ON BEHALF OF THE ARRO EXECUTIVE COMMITTEE

YESTERDAY, DURING THE ARRO ANNUAL SEMINAR, we presented the results of the 2022 Graduating Resident Survey. For the third year in a row, we succeeded in having a reasonably high response rate with over 80% of graduating residents completing this year’s survey. With regard to employment, 95% of survey respondents noted having a signed contract by June 2022. As compared to prior years of the Graduating Resident Survey in which respondents felt that there was a substantial impact of COVID-19 on the job search, about 70% of respondents said “no” when asked if there was a continuing impact of COVID-19. For those who felt the impact of COVID-19 on their search, a number listed that there were more screening interviews, but fewer on-site interviews or actual job offers as a consequence.

Of the residents who accepted positions, about 52% were employed by an academic center, 34% were employed by a private practice (either free-standing or hospital-based), and 14% were employed by hospitals; 99% of accepted positions were full-time, and 13% were rural (with 37% suburban and 50% urban). An interesting deviation from last year’s data was the percentage of individuals accepting generalist versus specialist positions. Whereas last year’s Graduating Resident Survey indicated that most respondents held generalist positions, this year’s data shows 55% of respondents being hired as disease site specialists and 45% of respondents being hired to generalist positions. More than two-thirds of survey respondents had contracts that came with a form of non-compete provision.

Expected first-year compensation (excluding those pursuing fellowships, n=129) ranged from $150-750k with a median of $360k (IQR: $325-420k). This median was found to increase to $400k (n=116; IQR: $350-465k) for the second year in practice. While the median first-year salary was $325-360k for those entering freestanding or hospital-based private practice, the median starting salary for those entering hospital-employed/community practice main campus or satellite positions was higher at $540k. The median salary for those pursuing clinical-track academic positions at a main site was $360k, and those entering positions at satellite facilities of academic centers had a median starting salary of $400k.

Of 42 individuals pursuing a partnership track for their practice, time to partnership was most frequently two to three years in length; 22% reported no financial buy-in. Of the 43% of respondents who reported a financial buy-in, the most common buy-in was $5,000 with a range of nominal fees up to $65,000. Ultimate compensation for private practice partners was reported by 42 respondents and ranged from $430k-1.4M with a median of $600k.

72% of survey respondents received an educational fund (median: $5,000). 67% received funding for moving expenses (median: $10,000). 57% received a signing bonus (median: $25,000). Overall, 66% of respondents rated themselves as “very satisfied” with the position they were entering, with 25% rating themselves as “satisfied.” ARRO extends its thanks and gratitude to the participating graduates of the Class of 2022 for completing the annual ARRO Graduating Resident Survey and providing this important information for future job applicants currently in training. We kindly request members of the Class of 2023 to continue the tradition of helping others by completing this survey next summer prior to graduating residency.

ARRO Executive Committee

2022 ANNUAL MEETING PROMOTIONAL SPONSORS

Current as of October 15, 2022

Thank you to our promotional sponsors for your generous support of ASTRO’s Survivor Circle.
Innovations at ASTRO 2022

Comfort Marker 2.0
Patient Marking System

Pediatric ProForm™
Head & Neck Solution

Visit us at Booth #3766

TotalRT
All in One Solution

Evolve Breastboard

info@CivcoRT.com | www.CivcoRT.com
The Product Showcase is prominently displayed directly outside the the Exhibit Hall. View products by category to see photos, videos and detailed information about each product. You can also view the Product Showcase via the MyASTROApp, the official meeting app, and the Conference Planner at www.astro.org/conferenceplanner.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Booth Number</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>3D Systems</td>
<td>2727</td>
<td>VSP® Bolus</td>
</tr>
<tr>
<td>Accuracy</td>
<td>2586</td>
<td>Radixact®</td>
</tr>
<tr>
<td>Advanced Accelerator Applications, Inc., A Novartis Company</td>
<td>2931</td>
<td>PLL/VICTOTM (lutetium Lu 177 Vyiviotide Tetraxtan)</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>3753</td>
<td>China AXess</td>
</tr>
<tr>
<td>Accuray</td>
<td>2595</td>
<td>SpaceOAR Vue™ Hydrogel</td>
</tr>
<tr>
<td>Accuray</td>
<td>2931</td>
<td>DecisionDx™-SCC</td>
</tr>
<tr>
<td>BEijing HGPT Technology &amp; Trade Co., Ltd.</td>
<td>2595</td>
<td>China AXess</td>
</tr>
<tr>
<td>Boston Scientific</td>
<td>1361</td>
<td>SpaceOAR Vue™ Hydrogel</td>
</tr>
<tr>
<td>Castle Biosciences, Inc.</td>
<td>1996</td>
<td>DecisionDx™-SCC</td>
</tr>
<tr>
<td>GE Healthcare</td>
<td>3736</td>
<td>AIR™ RT package</td>
</tr>
<tr>
<td>GE Healthcare</td>
<td>3736</td>
<td>Revolution Apex Platform with Spectral Imaging, Volume 4D Technologies and MaxFOV2</td>
</tr>
<tr>
<td>LAP of America Laser Applications, L.L.C.</td>
<td>2966</td>
<td>RadCalc</td>
</tr>
<tr>
<td>LAP of America Laser Applications, L.L.C.</td>
<td>2966</td>
<td>RadCalc</td>
</tr>
<tr>
<td>Leo Cancer Care</td>
<td>4570</td>
<td>Marie™</td>
</tr>
<tr>
<td>Leo Cancer Care</td>
<td>1394</td>
<td>Marie™</td>
</tr>
<tr>
<td>Macromedics</td>
<td>1786</td>
<td>Flexboard™ - EagleBoard™-2</td>
</tr>
<tr>
<td>MIM Software Inc.</td>
<td>1786</td>
<td>Flexboard™ - EagleBoard™-2</td>
</tr>
<tr>
<td>MIM Software Inc.</td>
<td>1786</td>
<td>Contour ProtégéAI</td>
</tr>
<tr>
<td>ViewRay, Inc.</td>
<td>3770</td>
<td>MRIdian A3i</td>
</tr>
<tr>
<td>Qfix</td>
<td>1761</td>
<td>Alta™ AirShuttle™</td>
</tr>
<tr>
<td>Triplet State Technology, LLC</td>
<td>1940</td>
<td>Magnetic Field Generator</td>
</tr>
<tr>
<td>TheraPanacea</td>
<td>3004</td>
<td>Adapt-Box (ART-PlantTM)</td>
</tr>
<tr>
<td>TheraPanacea</td>
<td>3004</td>
<td>Adapt-Box (ART-PlantTM)</td>
</tr>
<tr>
<td>The Phantom Laboratory</td>
<td>1159</td>
<td>Magphan® RT</td>
</tr>
<tr>
<td>Therapanea</td>
<td>3004</td>
<td>Magnetic Field Generator</td>
</tr>
<tr>
<td>Therapanea</td>
<td>3004</td>
<td>Magnetic Field Generator</td>
</tr>
<tr>
<td>Therapanea</td>
<td>3004</td>
<td>Magnetic Field Generator</td>
</tr>
</tbody>
</table>
Leadership Pathway Program participants give annual reports at Board of Directors meeting

AT THIS YEAR’S BOARD OF DIRECTORS meeting, ASTRO’s leadership pathway participants — both those in their first and second years of the program — presented reports on their experiences. The Leadership Pathway Program (LPP) is a career opportunity designed to enhance diversity among ASTRO’s leadership and help proactively develop the next generation of organizational leaders.

Dayssy Alexandra Diaz Pardo, MD, Assistant Professor and Vice Chair of DEI at The Ohio State University, summarized both years of their time in the program. Dr. Diaz Pardo focused on the Annual Meeting and served on its steering committee. Increasing the diversity of speakers at the Annual Meeting has been an organizational goal for several years, and Dr. Diaz Pardo worked with organizational leadership to improve representation at the meeting. In terms of future directions, Dr. Diaz Pardo highlighted the creation of a DEI leaders’ group, as well as the opportunity to partner with outside organizations to deliver more information about radiation oncology to populations that are underrepresented in the field.

Julianne Pollard-Larkin, PhD, of MD Anderson Cancer Center, spoke passionately about how they have been empowered by advocacy — and by their experiences working with the Advocacy Division of ASTRO. “This program gives me that extra oomph!” Dr. Pollard-Larkin exclaimed, speaking about LPP’s impact. In addition to participating in their first Advocacy Day in 2021, Dr. Pollard-Larkin joined the CHEDI Advocacy and Community Outreach Committee, planned a joint AAPM EDIC - ASTRO HEDI documentary screening for “Black Men in White Coats,” and created a GR advocacy advertisement to recruit more ASTRO members.

In introducing Kosj Yamoah, MD, PhD, now Chair of the Department of Radiation Oncology at the Moffitt Cancer Center, Curtiland Deville, MD, of Johns Hopkins University, said Dr. Yamoah had eclipsed the pathway program — a realization that drew laughter and applause. Dr. Yamoah participated in the Health Policy Health Equity Work Group and the Health Policy Council. Dr. Yamoah’s work with the Health Policy Council focused on the RO Model and the role of health equity in future payment models. “Ensuring alignment between identified equity issues and adequate resources to address them will be a challenge,” Dr. Yamoah said.

Raymond Mailhot-Vega, MD, of the University of Florida presented on their first year, where they participated in grant reviewing and Annual Meeting track reviewing and facilitated an ASTRO ROCKS session on NCI Diversity Supplements and Other Awards Targeting Underrepresented Populations. They emphasized the need to connect researchers with available funding.

Michelle S. Ludwig, MD, MPH, PhD, Associate Professor of Radiation Oncology at Baylor College of Medicine, spoke about participating in the Health Policy Committee, the HEDI Advocacy and Community Engagement Committee, and the Early Career Committee. While they have been busy collaborating with those committees through the first year of the program, they are choosing to focus on climate change and its effects on cancer treatment disparities in their second year.

Sophia C. Kamran, Assistant Professor of Radiation Oncology at Harvard Medical School, spoke about their work with the Clinical Affairs and Quality Council. Importantly, Dr. Kamran launched a project to examine the diversity of guidelines task forces. Women and ethnic/racial minorities have been historically underrepresented in such task forces, and Dr. Kamran, along with the CAQC, is aiming to improve data collection on this issue in order to address the disparities.

All participants in the Leadership Pathway Program commended the effect the program has had on their careers and thanked ASTRO leadership and staff.

GREAT MINDS FOR GRAND CHALLENGES

GLOBAL RECRUITMENT at The University of Hong Kong

The Medical Faculty of the University of Hong Kong has launched a global recruitment campaign to recruit 140 clinical and non-clinical professoriate staff ahead of our 140th anniversary in 2027. We look forward to meeting interested academics. Visit www.med.hku.hk/140for140 to learn more about the campaign.
### Presidential Symposium Schedule of Events

**Sunday, October 23**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Introduction</strong></td>
<td>12:00 p.m. – 12:05 p.m.</td>
<td>Geraldine Jacobson, MD, MPH, MBA, FASTRO, ASTRO President</td>
</tr>
<tr>
<td><strong>Session I • AI Opportunities in Today’s Patient’s Journey — Cutting-Edge AI in Radiation Oncology</strong></td>
<td>12:05 p.m. – 1:00 p.m.</td>
<td>Miss Sanjay Aneja, MD</td>
</tr>
<tr>
<td>Introductions</td>
<td></td>
<td>Catherine C. Park, MD, FASTRO</td>
</tr>
<tr>
<td>Current Progress of Machine Learning in Radiation Oncology</td>
<td>Sanjay Aneja, MD</td>
<td></td>
</tr>
<tr>
<td>The State of the Art in Digital Pathology and AI: Progress in Prostate Cancer</td>
<td>Osama Mohamad, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>Clinical Integration of Machine Learning for Curative-Intent Radiation Treatment of Patients with Prostate Cancer</td>
<td>Alejandro Berlin, MD, MS</td>
<td></td>
</tr>
<tr>
<td>Wide-Scale Clinical Adoption of Automated Knowledge-Based Planning</td>
<td>Kevin L. Moore, PhD</td>
<td></td>
</tr>
<tr>
<td>Panel Discussion - How Will AI Tools Be Presented</td>
<td>Todd Pawlicki, PhD, FASTRO Catherine C. Park, MD, FASTRO</td>
<td></td>
</tr>
<tr>
<td><strong>Session II • Prevention and Mitigation of Radiation Toxicity</strong></td>
<td>1:00 p.m. – 2:00 p.m</td>
<td>Brian Marples, PhD</td>
</tr>
<tr>
<td>Introductions</td>
<td></td>
<td>Brian Marples, PhD</td>
</tr>
<tr>
<td>Inherited Susceptibility to Normal Tissue Toxicity: Towards Personalized Radiotherapy and Radioprotection</td>
<td>Sarah L. Kerns, PhD, MPH</td>
<td></td>
</tr>
<tr>
<td>Normal Tissue Injury, Specifically in the Cardiovascular System</td>
<td>Carmen Bergom, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>Radiation-Induced CNS Damage: Potential Strategies for Preserving Cognitive Function</td>
<td>Catherine M. Davis-Takacs, PhD</td>
<td></td>
</tr>
<tr>
<td>Patient-Centered Clinical Trials on Radiation Toxicity: How the Patient Experience Guides Study Design</td>
<td>Ryan T. Hughes, MD</td>
<td></td>
</tr>
<tr>
<td>Panel Discussion</td>
<td>Moderator and all speakers</td>
<td></td>
</tr>
<tr>
<td><strong>Session III • The “Meta” Vision — How Can AI Help Solve Issues of Equity/Access/Value in Radiation Oncology?</strong></td>
<td>2:00 p.m. – 3:00 p.m</td>
<td>Julian C. Hong, MD, MS</td>
</tr>
<tr>
<td>Introductions</td>
<td></td>
<td>Julian C. Hong, MD, MS</td>
</tr>
<tr>
<td>Social Determinants of Health and How That Can Fit Into Bringing DEI and Access to our Patients and Practices</td>
<td>Charles Mayo, PhD, FASTRO</td>
<td></td>
</tr>
<tr>
<td>AI and Medical Knowledge</td>
<td>Nadine Housri, MD</td>
<td></td>
</tr>
<tr>
<td>AI-Based Clinical Trials</td>
<td>James Zou, PhD</td>
<td></td>
</tr>
<tr>
<td>Using AI to Benefit Our Patients: Clinical Trials, Implementation and Beyond</td>
<td>Julian C. Hong, MD, MS</td>
<td></td>
</tr>
<tr>
<td>Impact of AI on Quality of Care, Clinical Practice and Training</td>
<td>Erin F. Gillespie, MD</td>
<td></td>
</tr>
<tr>
<td>Panel Discussion</td>
<td>Moderator and all speakers</td>
<td></td>
</tr>
<tr>
<td><strong>Session IV • Human Doctors, Human Patients</strong></td>
<td>3:00 p.m. – 4:00 p.m</td>
<td>Geraldine Jacobson, MD, MBA, MPH, FASTRO</td>
</tr>
<tr>
<td>Introductions</td>
<td></td>
<td>Geraldine Jacobson, MD, MBA, MPH, FASTRO</td>
</tr>
<tr>
<td>Looking in the Mirror: What I Didn’t Know as an Oncologist Until I Became a Cancer Patient</td>
<td>Rachel Abrams Rabinovitch, MD, FASTRO</td>
<td></td>
</tr>
<tr>
<td>Quality of Life and the Sexual Self in Cancer Patients</td>
<td>Sage Bolte, PhD</td>
<td></td>
</tr>
<tr>
<td>Digital Empathy</td>
<td>Sarah Hoffe, MD</td>
<td></td>
</tr>
<tr>
<td>Panel Role Play - Understanding What's Really Going on: Cognitive Biases and Emotional Intelligence in Radiation Oncology</td>
<td>Sarah Hoffe, MD Benjamin William Corn, MD, FASTRO Ronald D. Ennis, MD, FASTRO Neha Vapiwala, MD, FASTRO Sarah Krug, MS, Patient Advocate and Advisor</td>
<td></td>
</tr>
<tr>
<td>Closing/Hope</td>
<td>Benjamin William Corn, MD, FASTRO</td>
<td></td>
</tr>
</tbody>
</table>
A clinical trial for people with head and neck cancer.

TrilynX Clinical Trial is studying an investigational option for previously untreated patients with locally advanced squamous cell carcinoma of the head and neck.

To learn more, please visit ClinicalTrials.gov
https://clinicaltrials.gov/ct2/show/NCT04459715

The TrilynX study is using an investigational compound that has not been proven to be safe or effective by any health authority.
CONGRATULATIONS

to the 2022 Annual Meeting Abstract Award Winners

Each year, ASTRO awards up to 45 investigators who submitted an abstract to the Annual Meeting with an achievement award. Winners are chosen based on their peer-reviewed scores and final abstract review by the Annual Meeting Steering Committee. There were over 2,000 abstract submissions this year, and 42 authors received an award. ASTRO encourages research in radiation oncology through the support of students, residents and early to mature career professionals. Congratulations to these individuals!

Resident Clinical/Basic Science Research Award
This award acknowledges clinical research being performed by young scientists. It is granted to the top resident author of a significant study in radiobiology, clinical research and physics. The award includes an honorarium, a certificate of recognition and a complimentary registration to the Annual Meeting.

Jared Hara, MD
University of Chicago Medical Center (Biology)

Kathryn Tringale, MD, MS
Memorial Sloan Kettering Cancer Center (Clinical)

Samuel Zhang, MD
Cedars-Sinai Medical Center (Physics)

International Abstract Award
The international award fosters continuing medical education, assists in career development and helps establish relationships with ASTRO members who may serve as scientific mentors to the recipient. Only one award is given each year to a candidate who receives the highest score among applicants. The award enables international early career radiation oncologist to travel to the U.S. and visit a comprehensive cancer center for one week, usually before or after the Annual Meeting. The award includes an honorarium, a certificate of recognition and a complimentary registration to the Annual Meeting.

Pallavi Kalbande, MD, MBBS
Mahatma Gandhi Institute of Medical Sciences

Nurse Abstract Award
This award promotes clinical research among radiation oncology nurses. Up to two awards are presented to the highest rated abstract submitters with a nursing designation. The winners receive a certificate of recognition and complimentary registration to the Annual Meeting.

Charles Huang, BS, MS
Stanford University

Annual Meeting Travel Awards
This award recognizes outstanding abstracts submitted by early career scientists, biologists and physicists. Up to 15 awards are given (five in each category) to offset travel expenses to the meeting.

Eric Zhao, MD, PhD
University of Toronto

Devin Miles, PhD
Johns Hopkins University School of Medicine

N. Ari WiJentunga, MD, PhD, MS
Memorial Sloan Kettering Cancer Center

Juliana Bronk, MD, PhD
The University of Texas MD Anderson Cancer Center

Joseph Lombardo, DO
Sidney Kimmel Medical College & Cancer Center at Thomas Jefferson University

Justin Barnes, MD, MS
Washington University School of Medicine in St. Louis

Omran Saifi, MD
Mayo Clinic

Kevin Tyan, BA
Harvard Medical School

Soumyajit Roy, MBBS
Rush University Medical Center

Brian De, MD
The University of Texas MD Anderson Cancer Center

Hua-Chieh Shao, PhD
UT Southwestern Medical Center

Hassan Jassar, PhD
Medical College of Wisconsin

Xinyi Li, MS
Duke University Medical Center

Kaylie Cullison, BS
University of Miami Miller School of Medicine

Xiaojian Chen, PhD
Medical College of Wisconsin
Basic/Translational Science Award

This award encourages participation in the ASTRO Annual Meeting by basic and translational scientists. Up to 12 awards are given to applicants having the top-rated abstracts in clinical research, radiobiology and physics categories. Winners are a mixture of junior and senior level investigators. The award includes an honorarium, a certificate of recognition and a complimentary registration to the Annual Meeting.

Matthew Deek, MD  
*Johns Hopkins Medicine* (Junior Investigator, Biology)

Jie Deng, MD, PhD  
*University of California, Los Angeles* (Junior Investigator, Biology)

Heather Conti, PhD  
*University of Toledo* (Senior Investigator, Biology)

David Routman, MD  
*Mayo Clinic* (Junior Investigator, Clinical)

Benjamin Kann, MD  
*Brigham and Women’s Hospital/Dana-Farber Cancer Institute* (Junior Investigator, Clinical)

Yunze Yang, PhD  
*Mayo Clinic Arizona* (Senior Investigator, Clinical)

Christian Guthier, PhD, MS  
*Artificial Intelligence in Medicine (AIM) Program at Harvard* (Senior Investigator, Clinical)

Mahbubur Rahman, PhD  
*Dartmouth College* (Junior Investigator, Physics)

Ergys Subashi, PhD  
*Memorial Sloan Kettering Cancer Center* (Senior Investigator, Physics)

Yuting Lin, PhD  
*University of Kansas Medical Center* (Senior Investigator, Physics)

Resident Recognition Awards

The Resident Recognition awards acknowledge outstanding abstracts submitted by early career scientists, biologists and physicists that were accepted into one of two presentation types — Quick Pitch Oral Scientific Session or Digital Poster Viewing. Up to 12 awards are given (up to three in each category). Winners receive a trophy to recognize their achievement.

Resident Recognition Award - Quick Pitch

Oscar Padilla, MD  
*Tufts University School of Medicine* (Biology)

Anupam Rishi, MD  
*Moffitt Cancer Center* (Clinical)

John Nikitas, MD  
*University of California, Los Angeles* (Physics)

Resident Recognition Award - Poster Viewing

Aaron Bush, MD  
*Mayo Clinic* (Biology)

Anne de Haan, MSc  
*University of Groningen* (Biology)

Hiroaki Ogawa, MD  
*Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital* (Biology)

Jun-yan Li, MD  
*Sun Yat-sen University Cancer Center* (Clinical)

Curtis Clark, MD, PhD  
*UAB Haz尔gul Salter Radiation Oncology Center* (Clinical)

Scarlett Acklin, MD  
*Duke University* (Clinical)

Hyunsoo No, MD, CMD  
*Stanford University School of Medicine* (Physics)

Haley Perlow, MD  
*The Ohio State University Wexner Medical Center* (Physics)

Hima Musunuru, MD, FRCR  
*UPMC Hillman Cancer Center* (Physics)
INDUSTRY-EXPERT THEATERS

SUNDAY, OCTOBER 23

<table>
<thead>
<tr>
<th>Theater 1</th>
<th>Theater 2</th>
<th>Room 216, Meeting Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 a.m. – 12:00 p.m.</td>
<td>11:00 a.m. – 12:00 p.m.</td>
<td>11:00 a.m. – 12:00 p.m.</td>
</tr>
<tr>
<td>Accuray Incorporated</td>
<td>Castle Biosciences, Inc.</td>
<td>Blue Earth Diagnostics, Inc.</td>
</tr>
<tr>
<td>AI: Adapt Intelligently</td>
<td>Personalized Risk Assessment for High-Risk Squamous Cell Carcinoma Patients</td>
<td>Emerging Data on the Impact of Axumin® (Fluciclovine F 18) PET Imaging on Radiotherapy Decisions</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Theater 1</th>
<th>Theater 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00 p.m. – 5:00 p.m.</td>
<td>4:00 p.m. – 5:00 p.m.</td>
</tr>
<tr>
<td>GE Healthcare</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>The Future of Radiation Therapy Interoperability: From Complex Care Coordination to Enhanced Collaboration</td>
<td>The Role of Radiation Oncology in Managing Patients with Unresectable Stage III Non-Small Cell Lung Cancer</td>
</tr>
</tbody>
</table>

INDUSTRY SATELLITE SYMPOSIA

Sunday, October 23, 2022  |  6:00 p.m. – 8:00 p.m.
Harnessing Novel Synergies with Tumor Treating Fields: Insights on Improving Survival with Multimodal Care in Aggressive Tumors

Location: Grand Hyatt San Antonio
Texas Ballroom Salon A/B
600 E. Market Street
San Antonio, TX 78205

6:00 p.m. – 6:30 p.m.: Registration and Dinner
6:30 p.m. – 8:00 p.m.: Symposium

Accreditation: In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

CME Credits: PVI, PeerView Institute for Medical Education, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience: This activity has been designed to meet the educational needs of radiation oncologists, medical oncologists, neuro-oncologists and other health care professionals involved in the care of patients with solid tumors.

Learning Objectives:
Upon completion of this activity, participants should be better able to:
1. Cite the mechanistic rationale and clinical evidence on use of novel locoregional therapies (LRTs), such as tumor treating fields (TTFields), in the treatment of patients with glioblastoma multiforme (GBM) or malignant pleural mesothelioma (MPM)
2. Assess recent clinical trial evidence on emerging multimodal strategies incorporating TTFields across various solid tumor malignancies, including thoracic, abdominal, and gynecologic cancers
3. Incorporate TTFields into multimodal treatment plans, including in the context of clinical trials, for appropriately selected patients with GBM, MPM, and other solid tumors
4. Employ evidence and team-based strategies to mitigate and manage AEs associated with novel LRTs (eg, TTFields) in patients with solid tumors

Visit the Exhibit Hall

Halls 2–4

Learn more about the latest products in cancer treatment and care in the Exhibit Hall.

Open 10:00 a.m. – 5:00 p.m.,
Sunday, October 23 – Tuesday, October 25.

Exhibit Hall Networking Reception
Monday, October 24, 4:00 p.m. – 5:00 p.m.

All registered attendees are invited to the Exhibit Hall Networking Reception hosted by ASTRO and participating exhibiting companies. This is a great opportunity for you to meet with industry partners over a beverage and refreshments while learning about the latest products, technology and services. Your complimentary drink ticket is included with your registration materials.

ASTRO RESOURCE CENTER
Main Lobby, Street Level

ASTRO representatives are available to answer questions about the Annual Meeting, ASTRO membership, continuing education, MOC requirements, session and meeting evaluations, and provide information on any of ASTRO’s products and services. Additionally, badge ribbons are available for pick up for 25-year members, APEX participants, RO-ILS participants and ASTROnews Editorial Board members.

The booth is open today through Wednesday afternoon.

SurvivorCircle
Main Lobby, Street Level

Stop by the Survivor Circle booth to meet this year’s recipients of the Survivor Circle Grants: Breast Cancer Resource Center and ThriveWell Cancer Foundation. While there, fold an origami crane. According to Japanese tradition, folding 1,000 paper cranes gives a person a chance to make one special wish come true. Help us reach our goal of 1,000 cranes and make a wish for the comfort and healing of our cancer patients.

Survivor Circle grants are generously funded by Annual Meeting sponsors.
Industry-Expert Theater

Controversies and Myths about Prostate Cancer Rectal Spacing

Monday, Oct. 24, 2022
12:00 – 1:00 pm CT
Room 216, Meeting Level
Lunch will be provided*

MODERATOR

Sean P. Collins, MD, PhD
Associate Professor of Radiation Medicine at Georgetown
University School of Medicine, Washington, D.C.
Director of the CyberKnife Prostate Program at MedStar
Georgetown University Hospital, Washington, D.C.

PRESENTERS

Top Five Myths of Prostate Cancer Rectal Spacing
Brian J. Davis, MD, PhD
Professor of Radiation Oncology,
Rochester, MN

Who Benefits the Most from Hydrogel Rectal Spacing?
Neil K. Taunk, MD, MSCTS
Director, Brachytherapy at PennMedicine
Director, Imaging Sciences, Asst Professor of
Radiation Oncology and Radiology,
Hospital of the University of Pennsylvania

Optimizing the Safety, Quality and Reproducibility of Rectal Spacing
Michael J. Zelefsky, MD
Professor of Radiation Oncology, Chief,
Brachytherapy Service, Director of GU
Radiation Oncology, Memorial Sloan
Kettering Cancer Center, New York, NY

ASTRO Annual Meeting 2022 | Visit booth #1361

*This invitation is extended only to Healthcare Providers. Spouses and other guests are not permitted to attend. Vermont licensed physicians are not permitted to attend. Additionally, Government employees should consult with their agency’s or institution’s ethics officer or ethics committee to confirm your attendance is permitted.

The Industry-Expert Theater content and views expressed therein are those of the Exhibitor and not of ASTRO.

All trademarks are the property of their respective owners. ©2022 Boston Scientific Corporation or its affiliates. All rights reserved. URO-1368409-AA SEP 2022
Best GammaBeam™ 100/300 Equinox™ Teletherapy System
with Avanza™ 6D Patient Positioning Table

With NEW Multi-Leaf Collimator for 80 and 100 cm SAD units — IMRT, IGRT, SRS, SBRT and Tomotherapy capable with ActiveRx

Patent Pending

Best® Iodine-125 Seed
Best™ Palladium-103 Seed
Best™ Localization Needles with I-125 Seeds

Best™ Fiducial Markers

Best™ Sonalis™ Ultrasound Imaging System

Best™ HDR Remote Afterloader

Best™ Localisation Needles with I-125 Seeds

Best™ Sonalis™ Ultrasound Imaging System

Best™ Treatment Planning System

Best™ HDR Remote Afterloader

MobileMOSFET Wireless Dosimetry System